The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Series A | Alive

Total Raised


Last Raised

$12M | 5 yrs ago

About Sentien Biotechnologies

Sentien Biotechnologies is a private, preclinical stage regenerative medicine company that is developing cell based therapies for critical care. The company's lead product is being developed to treat severe Acute Kidney Injury, (AKI), the sudden loss of kidney function that can occur after cardiac surgery.

Sentien Biotechnologies Headquarter Location

196 Boston Avenue Suite 2200

Medford, Massachusetts, 02155,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Sentien Biotechnologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sentien Biotechnologies is included in 2 Expert Collections, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Sentien Biotechnologies News

Eloxx Pharmaceuticals Reports Second Quarter 2021 Financial and Operating Results and Provides Business Update

Aug 16, 2021

Waltham, Massachusetts, UNITED STATES Added Additional Treatment Arm and Provided Enrollment Update for Ongoing ELX-02 Phase 2 Clinical Trials for Cystic Fibrosis (CF) Nominated ZKN-013 as Lead Candidate for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and Junctional Epidermolysis Bullosa (JEB) Programs Advanced Multiple Preclinical Rare Inherited and Targeted Oncology Programs Received Funding Award from Cystic Fibrosis Foundation to Develop Ribosome Modulating Agents (RMAs) with TURBO-ZM™ Platform Raised Approximately $52M in Gross Proceeds Through Public Offering WATERTOWN, Mass., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today reported its financial results for the three months ended June 30, 2021, and provided a business update. “Since the acquisition of Zikani Therapeutics in early April, we have made tremendous progress across our portfolio of novel therapeutic programs,” said Sumit Aggarwal, President and Chief Executive Officer of Eloxx. “In CF, we remain on track to report data from the ongoing Phase 2 clinical trials for ELX-02, while we are also preparing for combination studies of ELX-02 and ivacaftor and commencing efforts to evaluate inhaled delivery of ELX-02. Beyond CF, we continue to advance our preclinical programs to demonstrate the potential of our oral RMAs. We intend to provide additional insight into these programs in the coming quarters.” Second Quarter 2021 and Subsequent Highlights Class 1 Cystic Fibrosis Ongoing ELX-02 Phase 2 clinical trials in CF patients affected by nonsense mutations in the CFTR (CF transmembrane conductance regulator) gene are designed to evaluate the safety of ELX-02 and assess short-term biological activity in patients. As previously announced, based on enrollment as of the end of June 2021, we remain on track to report data from the monotherapy arms of the ELX-02 clinical trials in the fourth quarter of 2021. We are continuing to enroll additional patients to support Phase 3 clinical trial planning. Biological activity is being assessed by changes in sweat chloride, a surrogate marker for restoring CFTR activity. For comparison, Orkambi, an FDA-approved CF agent, demonstrated mid-single digit reductions in sweat chloride over one- to two-week study durations in a similar trial setting. Patient dosing in the expansion arm, which includes a combination of ELX-02 and the CFTR protein potentiator, Kalydeco (ivacaftor), is expected to begin by the end of 2021. Previously disclosed preclinical organoid experiments have demonstrated that the addition of Kalydeco to ELX-02 can enhance activity up to three-fold. Safety Review Committee has approved advancement to highest dose level to be studied. Began evaluation of inhaled (nebulizer-based) delivery of the current subcutaneous formulation of ELX-02. Preclinical rodent studies of ELX-02 and other aminoglycosides have demonstrated 30- to 100-fold higher drug concentration in the lung versus plasma. This has the potential to further improve the activity of ELX-02 as both a single agent and in combination with other drugs. Received an award of up to $2.6M from the Cystic Fibrosis Foundation to identify optimized oral Ribosome Modulating Agents (RMAs) with our TURBO-ZM™ Platform for further development for the treatment of CF patients with nonsense mutations. Recessive Dystrophic Epidermolysis Bullosa (RDEB) and Junctional Epidermolysis Bullosa (JEB) Nominated ZKN-013 as the drug candidate to move into IND-enabling studies for the treatment of RDEB and JEB. Good Laboratory Practice (GLP) safety studies are expected to begin by the end of 2021. We remain on track to file an IND submission in 2022. In preclinical experiments, treating RDEB patient-derived fibroblasts and keratinocytes with ZKN-013 showed clinically relevant restoration of full-length Collagen 7A (COL7A) across multiple genotypes in a dose dependent manner. In a non-GLP animal toxicity study, ZKN-013 demonstrated a substantial safety margin with therapeutically sufficient drug levels in skin with chronic dosing. Rare Inherited and Targeted Oncology Continued to advance our preclincial oncology pipeline, which is focused on rare inherited cancers with driver nonsense mutations and cancers with driver mutations in the ribosome. Our lead program is for the treatment of patients with Familial Adenomatous Polyposis (FAP). We have initiated an 8-week study in APCMin (multiple intestinal neoplasia) mice to evaluate the potential of RMAs to treat FAP. The APCMin mouse is a translationally validated model for drug development for FAP. Prior studies of erythromycin in APCMin mice showed reductions in colon polyps that successfully translated to demonstrating clinical efficacy.1 This study in APCMin will evaluate polyp number and size in ZKN013 treated mice versus control mice. We expect to report results from this study in the fourth quarter of 2021. Initiated cancer cell line and xenograft mouse studies to evaluate the response to treatment with RMAs to advance first-in-class onco-ribosome targeted inhibitors for oncology therapy. Corporate An underwritten public offering of 38,333,334 shares of common stock, including the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $1.35 per share was closed in May 2021. Aggregate gross proceeds from the offering were approximately $51.75 million, before deducting underwriting discounts and commissions and offering expenses. Pedro Huertas, M.D., Ph.D., joined Eloxx as a Senior Adviser. Dr. Huertas previously served as CMO of Eloxx. He has also served as CMO of Inozyme Pharma and Sentien Biotechnologies and in various roles at Pfizer, Shire, Massachusetts General Hospital, and Genzyme. Second Quarter 2021 Financial Results For the three months ended June 30, 2021, we incurred a net loss of $36.1 million or $0.54 per share, which includes $4.0 million in stock-based compensation. For the same period in the prior year, we incurred a net loss of $7.9 million, or $0.20 per share. Results for the second quarter of 2021 included a $22.7 million acquired in-process research and development expense related to the acquisition of Zikani. Our research and development expenses (R&D) were $5.7 million for the three months ended June 30, 2021, which includes $0.1 million in stock-based compensation. For the same period in the prior year, R&D expenses were $3.7 million. The increase in R&D expenses was primarily related to an increase in expenses related to the continued development of ELX-02 as a result of the suspension of our clinical trials due to the impact of the COVID-19 pandemic in the prior year period and an increase in salaries and other personnel related costs, partially offset by a decrease in stock-based compensation expense. Our general and administrative (G&A) expenses were $7.4 million for the three months ended June 30, 2021, which includes $3.9 million in stock-based compensation. For the same period in the prior year, G&A expenses were $3.8 million. The increase was primarily related to an increase in stock-based compensation expense, an increase in salaries and other personnel-related costs associated with the merger with Zikani, as well as an increase in expenses attributable principally to infrastructure related costs including legal, accounting and other professional fees. As of June 30, 2021, we had cash and cash equivalents of $56.7 million, which we expect will be sufficient to fund our operations into the first quarter of 2023. 1 J Mol Med (Berl) 2016 Apr;94(4):469-82) and Int J Cancer 2020 Feb 15;146(4):1064-1074) About Eloxx Pharmaceuticals Eloxx Pharmaceuticals, Inc. is engaged in the science of ribosome modulation, leveraging its innovative TURBO-ZMTM chemistry technology platform in an effort to develop novel Ribosome Modulating Agents (RMAs) and its library of Eukaryotic Ribsome Selective Glycosides (ERSGs). Eloxx’s lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in clinical development, focusing on cystic fibrosis. Eloxx also has preclinical programs focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, including autosomal dominant polycystic kidney disease, as well as rare ocular genetic disorders. For more information, please visit . Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of present and historical facts contained in this press release, including without limitation, statements regarding our expected cash burn and future financial results, the expected timing of trials and results from clinical studies of our product candidates and the potential of our product candidate to treat nonsense mutations are forward-looking statements. Forward-looking statements can be identified by the words “aim,” “may,” “will,” “would,” “should,” “expect,” “explore,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “seeks,” or “continue” or the negative of these terms similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on management's current plans, estimates, assumptions and projections based on information currently available to us. Forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, and actual results or outcomes may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to: our ability to progress any product candidates in preclinical or clinical trials; the uncertainty of clinical trial results and the fact that positive results from preclinical studies are not always indicative of positive clinical results; the scope, rate and progress of our preclinical studies and clinical trials and other research and development activities; the competition for patient enrollment from drug candidates in development; the impact of the global COVID-19 pandemic on our clinical trials, operations, vendors, suppliers, and employees; our ability to obtain the capital necessary to fund our operations; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; our ability to obtain financial in the future through product licensing, public or private equity or debt financing or otherwise; general business conditions, regulatory environment, competition and market for our products; and business ability and judgment of personnel, and the availability of qualified personnel and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, as any such factors may be updated from time to time in our other filings with the SEC, accessible on the SEC’s website at and the “Financials & Filings” page of our website at All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact

Sentien Biotechnologies Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Sentien Biotechnologies Rank

  • Where is Sentien Biotechnologies's headquarters?

    Sentien Biotechnologies's headquarters is located at 196 Boston Avenue, Medford.

  • What is Sentien Biotechnologies's latest funding round?

    Sentien Biotechnologies's latest funding round is Series A.

  • How much did Sentien Biotechnologies raise?

    Sentien Biotechnologies raised a total of $13.05M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.